Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.

Vaccine 130

Vaccine Trials Animal Testing Virus 130

Drug Discovery World

JANUARY 12, 2024

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Despite the first outbreaks occurring 25 years ago in Malaysia and Singapore, there are currently no approved vaccines or treatments.

Virus 130

Virus Vaccine Trials Clinical Trials 130

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

SEPTEMBER 15, 2023

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Rabies, RBI-4000 and the Phase I trial Rabies remains a public health threat in several geographical regions and is designated an NIAID Priority Pathogen.

Vaccine 130

Vaccine Trials Immune Response Virus 130

Drug Discovery World

SEPTEMBER 18, 2023

Next generation Covid-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of the virus, extend the duration of protection, and offer better protection in the prevention of illness and transmission over the current state of vaccine technologies.

Clinical Trials 130

Clinical Trials Vaccine Trials Government 130

Drug Discovery World

MAY 30, 2024

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial?

Vaccine 148

Vaccine Protein Expression Clinical Trials Immune Response 148

Drugs.com

APRIL 12, 2024

FRIDAY, April 12, 2024 -- A chlamydia vaccine has triggered immune responses in an early trial, raising hopes that one day it might help curb the spread of the sexually transmitted infection (STI).There There is currently no vaccine for chlamydia, which.

Vaccine 115

Vaccine Trials Immune Response 115

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccine 130

Vaccine Trials Clinical Trials Virus 130

Drug Discovery World

FEBRUARY 27, 2024

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.

Vaccine 261

Vaccine Clinical Trials Disease Clinical Development 261

Drug Discovery World

APRIL 24, 2023

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. There is currently no vaccine available. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide.

Vaccine 130

Vaccine Trials Clinical Trials Disease 130

Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” months after initial treatment.

Vaccine 148

Vaccine Clinical Trials FDA Approval Research Laboratories 148

Drugs.com

JUNE 10, 2024

MONDAY, June 10, 2024 -- An experimental vaccine that could offer one-stop prevention for both COVID-19 and influenza is showing positive results among older adults in trials, maker Moderna announced Monday.The shot — for now called mRNA-1083 — "ha.

Vaccine 111

Vaccine Trials 111

Drug Discovery World

JUNE 10, 2024

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. This approval is also the first time an mRNA vaccine has been approved for a disease other than Covid-19.”

Vaccine 148

Vaccine FDA Approval FDA Virus 148

Drug Discovery World

APRIL 15, 2024

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV.

Vaccine 130

Vaccine Clinical Trials Trials Virus 130

Drug Discovery World

FEBRUARY 22, 2023

The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

Vaccine 130

Vaccine Trials FDA Disease 130

Science Daily: Pharmacology News

MAY 17, 2024

An HIV vaccine candidate triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

Vaccine 111

Vaccine Trials Clinical Trials 111

Drug Discovery World

APRIL 13, 2023

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. The vaccine has been approved for use in children aged five to 36 months, the age group at highest risk of death from malaria.

Vaccine 246

Vaccine Clinical Trials Trials Production 246

Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccine 130

Vaccine Clinical Trials Trials Disease 130

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. By training the immune system to attack these regions, it gives protection against other coronaviruses not represented in the vaccine.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

AUGUST 15, 2022

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial. . The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). Kenya, where malaria is endemic. . Official comments . Fauci, M.D. “A

Vaccine 130

Vaccine Trials Clinical Trials Laboratories 130

Science Daily: Pharmacology News

APRIL 29, 2024

The first study of the use of microarray patches to vaccinate children has shown that the method is safe and induces strong immune responses.

Vaccine 106

Vaccine Trials Immune Response 106

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. References .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drugs.com

DECEMBER 15, 2023

15, 2023 -- A new melanoma vaccine has shown its mettle in battling the deadly skin cancer in a new trial. People with advanced melanomas who received the vaccine plus Merck's cancer drug Keytruda were 49% less likely to die or have. FRIDAY, Dec.

Vaccine 114

Vaccine Trials Treatment Drugs 114

Drug Discovery World

JANUARY 8, 2024

UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS).

Vaccine 148

Vaccine Clinical Trials Licensing Licensing 148

Drug Discovery World

MAY 1, 2024

Our preclinical results suggest that our vaccines may significantly outperform them, to transform care for future cancer patients.” It will also support development of Infinitopes’ lead asset, a novel cancer vaccine called ITOP1, which is scheduled to commence a Phase I/IIa study in first line cancer patients in the third quarter of 2024.

Vaccine 148

Vaccine Clinical Trials Research Science 148

Drug Discovery World

OCTOBER 11, 2023

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B streptococcus (GBS), has announced the completion of €54 million upsized financing. GBS is a leading cause of life-threatening infections in newborns as well as adverse pregnancy outcomes such as preterm delivery and stillbirths.

Vaccine 148

Vaccine Clinical Trials Trials Science 148

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Drug Discovery World

SEPTEMBER 19, 2023

The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector. There are currently no approved vaccines or treatments for Nipah virus infection. Seasonal outbreaks have occurred annually in Bangladesh since 2001.

Clinical Trials 163

Clinical Trials Virus Trials Vaccine 163

Drugs.com

MAY 2, 2024

THURSDAY, May 2, 2024 -- An experimental cancer vaccine can quickly reprogram a person’s immune system to attack glioblastoma, the most aggressive and lethal form of brain cancer, a small, preliminary study has found.The cancer vaccine is based.

Vaccine 103

Vaccine Trials 103

Drug Discovery World

MARCH 27, 2024

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. According to GlobalData, there are 11 vaccines in late-stage development for TB globally.

Vaccine 130

Vaccine Clinical Trials Licensing Licensing 130

Drug Discovery World

OCTOBER 3, 2023

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). The developers expect additional regulatory approvals will follow shortly and R21/Matrix-M vaccine doses could be ready to begin wider roll-out next year.

Vaccine 148

Vaccine Clinical Trials Licensing Licensing 148

Drugs.com

OCTOBER 6, 2023

announced Wednesday that it has seen positive early results with a new vaccine that would guard against four strains of flu plus COVID-19. In interim findings from a Phase 1/2 trial, the vaccine showed both a. THURSDAY, Oct. 5, 2023 -- Moderna Inc.

Vaccine 105

Vaccine Trials 105

Drug Discovery World

SEPTEMBER 18, 2023

Jonathan Riess, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC). These data were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC).

Vaccine 130

Vaccine Trials Therapies Treatment 130

Drug Discovery World

MARCH 15, 2024

Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. The company’s vaccine for Chikungunya virus (IXCHIQ) was approved by the US Food and Drug Administration (FDA) in November 2023 and is the world’s first and only vaccine for Chikungunya.

Vaccine 148

Vaccine Science Clinical Trials Virus 148

Drug Discovery World

JANUARY 18, 2024

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination. The results will assist researchers in designing vaccines which will offer greater protection to the most vulnerable.

Vaccine 130

Vaccine Clinical Research Hospitals Trials 130

Drugs.com

OCTOBER 11, 2023

11, 2023 -- New research points to the potential of a COVID-19 vaccine delivered through the nose. The phase 1 clinical trial showed that the product, administered nasally in two doses, delivered a significant immune response to. WEDNESDAY, Oct.

Vaccine 99

Vaccine Trials Immune Response Clinical Trials 99